RESYNCHRONIZATION
THERAPY DEVICES
Cardiac resynchronization therapy (CRT) is a proven
clinical treatment for heart failure management.
DISCOVER THE CRT RANGE
Abbott offers a variety of CRT options to help tailor the treatment to your patients. Our Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) can help you make a powerful difference in the lives of your heart failure patients.
GALLANT™ HF CRT-D
With a small, contoured design, the Magnetic Resonance (MR) Conditional Gallant™ HF CRT-D offers easier, faster, more effective CRT optimization with SyncAV PlusTM CRT technology and MultiPoint™ pacing (MPP).
ENTRANT™ HF CRT-D
The MR Conditional Entrant™ HF CRT-D with SyncAV™ CRT technology offers powerful heart failure therapy in a small, contoured design.
GALLANT™ AND ENTRANT™ HF CRT-Ds OFFER:
RIGHT ENERGY. RIGHT TIME. FOR GREATER FIRST-SHOCK SUCCESS1
Timing is everything when shocking a patient out of ventricular fibrillation (VF). Precision Shock Technology (PST) delivers the right energy within the right time for greater first-shock success.1–9 Any energy outside this response window is wasted.
LEARN MORE ABOUT PST:
SyncAV™ CRT technology provides the most QRS narrowing options at implant for patients.10 QRS narrowing after CRT implantation allows improved mortality. In patients with left bundle branch block (LBBB), QRS narrowing after CRT implant is associated with 2x lower mortality.11
Published rate of QRS narrowing at implant10
VENTRICULAR FIBRILLATION (VF) THERAPY ASSURANCE DECREASES TIME TO TREATMENT FOR ARRHYTHMIAS IN PATIENTS WHO ARE LIKELY TO BE HEMODYNAMICALLY UNSTABLE
VF Therapy Assurance is the only technology to provide an additional safety net for difficult-to-detect ventricular arrhythmias. Without VF Therapy Assurance, ventricular tachyarrhythmias with low and varying signal amplitudes may not be successfully identified.12,13
of patients who received high-voltage (HV) therapy due to VF Therapy Assurance’s enhanced detection would have been otherwise untreated for potentially life-threatening arrhythmias.12
OPTIMIZED PRECISION SHOCK TECHNOLOGY OFFERS NONINVASIVE PROGRAMMING OPTIONS TO OPTIMIZE RESCUE THERAPY TO EACH PATIENT’S UNIQUE PHYSIOLOGY AND CHANGING CONDITIONS
OPTIMIZED PRECISION SHOCK TECHNOLOGY is the industry’s most flexible option for the management of high defibrillation threshold (DFT). The algorithm supports a 10 Joules (J) shock safety margin for patients.14
- Enables smartphone connectivity through data encryption
- Compatible with the myMerlinPulse™ app
ABBOTT’S 1.5 TESLA (T) AND 3T MAGNETIC RESONANCE IMAGING (MRI)-READY SOLUTIONS* ENSURE NO LOSS OF CRT THERAPY FOR YOUR PATIENTS DURING FULL-BODY SCANS AND ALLOWS FOR PROGRAMMING OF AN MRI TIMEOUT**
MASTERING CRT IMPLANTS
Learn more about the practicalities of CRT implants in this video from EHRA 2025.
TV
TV
MORE-CRT MPP Video
Video Pfeiffer and markus Stühlinger
Video Pedro Marques + Ana Bernardes
The role of CRT - Carsten Israel
Optimizing CRT: From Conventional to LOT CRT
- Katcher M, Davis K, Badie N, et al. Improved ICD Shock Efficacy using Programmable Pulse Width. Presented at: Heart Rhythm Society; April 24-27, 2025.
- Swerdlow CD, Brewer JE, Kass RM, et al. Application of models of defibrillation to human defibrillation data: implications for optimizing implantable defibrillator capacitance. Circulation. 1997;96(9):2813-22. doi: 10.1161/01.cir.96.9.2813.
- Ellenbogen K, Wilkoff G, Kay G, et al. (2007). Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy (3rd ed.). Elsevier Saunders; 542-547. ISBN-13: 978-1- 4160-2536-8.
- Kawata U, Birgersdotter-Green U. (2018). Ventricular Fibrillation and Defibrillation, Encyclopedia of Cardiovascular Research and Medicine. Elsevier, 674-682. ISBN 9780128051542. doi: 10.1016/B978-0-12-809657-4.99764-3.
- Efimov I, Kroll M, Tchou P. (2009). Cardiac Bioelectric Therapy. Springer, 468-472. ISBN 978-0-387-79403-7.
- Kroll M, Lehmann M. (1996). Implantable Cardioverter Defibrillator Therapy. Kluwher Academic Publishers, 68-69.
- Gold MR, Shorofsky SR. Strength-duration relationship for human transvenous defibrillation. Circulation. 1997;96(10):3517-20. doi: 10.1161/01.cir.96.10.3517.
- Kroll MW, Swerdlow CD. Optimizing defibrillation waveforms for ICDs. J Interv Card Electrophysiol. 2007;18(3):247-63. doi: 10.1007/s10840-007-9095-z.
- Doshi SK, Pittaro MD, Reeves R, et al. Efficacy of tuned waveforms based on different membrane time constants on defibrillation thresholds: primary results from the POWER trial. Pacing Clin Electrophysiol. 2012;35(10):1253-61. doi: 10.1111/j.1540-8159.2012.03500.x.
- Varma N, O’Donnell D, Bassiouny M, et al. Programming Cardiac Resynchronization Therapy for Electrical Synchrony: Reaching Beyond Left Bundle Branch Block and Left Ventricular Activation Delay. J Am Heart Assoc. 2018;7(3):e007489. doi: 10.1161/JAHA.117.007489.
- Jastrzebski M, Baranchuk A, Fijorek K, et al. Cardiac resynchronization therapy-induced acute shortening of QRS duration predicts long-term mortality only in patients with left bundle branch block. Europace. 2019;21(2):281-289. doi: 10.1093/europace/euy254.
- Wilkoff BL, Sterns LD, Katcher MS, et al. Novel Ventricular Tachyarrhythmia Detection Enhancement Detects Undertreated Life-Threatening Arrhythmias. Heart Rhythm 02. 2021;3(1):70-78. doi: 10.1016/j.hroo.2021.11.0092021.
- Stroobandt RX, Duytschaever MF, Strisciuglio T, et al Failure to detect life-threatening arrhythmias in ICDs using single-chamber detection criteria. Pacing Clin Electrophysiology. 2019;42:583-594. doi:10.1111/pace.13610.3.
- Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71-75. doi: 10.1159/000345776.
™ indicates a trademark of the Abbott group of companies.
Bluetooth® and the Bluetooth® logo are registered trademarks of Bluetooth® SIG, Inc.